A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

(2011) Didier Decaudin et al.   Clinical Lymphoma Myeloma & Leukemia

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials

(2009) Loukia S. Poulou et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

(2009) Jane N. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY

Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response

(2009) C. Gisselbrecht et al.   ONCOLOGIST

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

(2008) Enrico Derenzini et al.   CANCER

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

(2008) R. Sud et al.   HAEMATOLOGICA

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

(2008) A. Martin et al.   HAEMATOLOGICA

High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation

(2008) Liliana Devizzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

(2007) Amrita Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY